MedTrace Logo

Escin in Patients With Covid-19 Infection

NCT04322344 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2020-09-16

No results posted yet for this study

Summary

In December 2019,a new type of pneumonia caused by the coronavirus (COVID-2019) broke out in Wuhan ,China, and spreads quickly to other Chinese cities and 28 countries. More than 70000 people were infected and over 2000 people died all over the world. There is no specific drug treatment for this disease. Considering that lung damage is related to both viral infection and burst of cytokines, our idea is to evaluate the efficacy and safety of escin as add-on treatment to conventional antiviral drugs in COVID-19 infected patients.

Conditions

  • Coronavirus Infections

Interventions

DRUG

Escin

treatment with escin or escinate sodium

DRUG

standard therapy

antiviral drugs

Sponsors & Collaborators

  • Azienda Ospedaliera Pugliese Ciaccio

    collaborator OTHER

  • Azienda Ospedaliera Universitaria Mater Domini, Catanzaro

    collaborator OTHER

  • University of Catanzaro

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-23
Primary Completion
2020-06-30
Completion
2020-12-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04322344 on ClinicalTrials.gov